Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check7 days agoChange DetectedSite-wide notice added about a lapse in government funding and NIH Clinical Center operations; Revision: v3.4.1 replaces v3.4.0.SummaryDifference0.3%

- Check14 days agoNo Change Detected
- Check15 days agoChange DetectedUI updates include displaying the glossary toggle and adding a 'Last Update Submitted that Met QC Criteria' label, and a 'No FEAR Act Data' note was added with the revision bumped to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check22 days agoChange DetectedRevision from v3.3.3 to v3.3.4 represents a minor update to the page, with no changes to study details or how users interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedThe footer now shows Revision: v3.3.3, and the HHS Vulnerability Disclosure link and the Revision: v3.3.2 entry have been removed. These changes do not affect the study information or page functionality.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no substantive changes to trial details, eligibility criteria, locations, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check80 days agoChange DetectedThe Publications section was updated: a sentence about voluntarily provided publications (revision 3.3.1) was added, and the previous sentence about study results (revision 3.2.0) was removed.SummaryDifference0.1%

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.